Strategies for postmarketing surveillance of drugs for rare diseases.
about
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countriesRett Syndrome: Crossing the Threshold to Clinical TranslationReview and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatmentsSystematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditionsMalignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference.Innovative research methods for studying treatments for rare diseases: methodological review.Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.Translational development of splice-modifying antisense oligomers.Orphan diseases: state of the drug discovery art.An innovative outcome-based care and procurement model of hemophilia management.Registries supporting new drug applications.An overview of the impact of rare disease characteristics on research methodology.Development and use of new therapeutics for rare diseases: views from patients, caregivers, and advocates.Ethical considerations in design of a study to evaluate a US Food and Drug Administration-approved indication: antivenom versus placebo for copperhead envenomation.Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases.
P2860
Q26748763-EB07B5C8-497C-47C0-8265-26A33615C966Q26772909-555EE8F5-36A3-4F97-AA6E-A80417D4D0F9Q26778142-02782EE6-446E-425B-9DC8-1CCEE353CA85Q28075766-D397FC76-8A39-4154-8C12-4EF3A6D54390Q34770934-FECA9CC8-0910-4956-9A8E-233683B6035FQ38271185-39CF0BAD-B612-4AD7-8461-9B0E262EDDB6Q38701074-9D239FCD-9B8D-4750-9909-3D6F94D094C2Q38996657-5340CDF0-0E8C-4E07-8C60-54642121458FQ45882722-827F85D6-B7E6-4928-B4E7-DCC3B4876D1BQ45884983-8C240442-02B7-4B96-B89D-58749D07EB2FQ47102430-F8098C0C-4F10-499C-97D2-80B9E1FEBEFEQ47558738-07B13AC5-BFBA-47CA-882E-7EEA03C9B673Q48061020-0673DE94-7C49-41B0-92E9-A1618979AB4EQ48070037-273774F7-9B7D-4E55-8563-D61D3B3C704FQ55457221-CF913141-092C-42A0-B6BC-2E5AF54EA13C
P2860
Strategies for postmarketing surveillance of drugs for rare diseases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Strategies for postmarketing surveillance of drugs for rare diseases.
@en
type
label
Strategies for postmarketing surveillance of drugs for rare diseases.
@en
prefLabel
Strategies for postmarketing surveillance of drugs for rare diseases.
@en
P2860
P356
P1476
Strategies for postmarketing surveillance of drugs for rare diseases
@en
P2093
P2860
P304
P356
10.1038/CLPT.2013.218
P407
P577
2013-11-05T00:00:00Z